Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

(ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF) 1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The ASX 200 healthcare stock received another FDA approval for its cancer detection product. The post Up 113% in a year, ...

As we expected, no-moat Telix’s slightly updated product, Gozellix, has received US regulatory approval. Like Illuccix, which contributes practically all of Telix’s current revenue ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial ...